Literature DB >> 29977805

Two-year outcomes of ab interno trabeculectomy with the Trabectome for Chinese primary open angle glaucoma: a retrospective multicenter study.

Ya-Long Dang1,2,3,4, Xiao Wang1, Wan-Wei Dai1,2,5, Ping Huang1, Nils A Loewen3, Chun Zhang1,2.   

Abstract

AIM: To evaluate the 2-year efficacy and safety of ab interno trabeculectomy with the Trabectome in Chinese primary open angle glaucoma (POAG) patients.
METHODS: This was a multicenter, retrospective, observational study and included POAG patients with or without visually-significant cataracts. The Chinese patients were enrolled from three glaucoma centers and a group of comparable Japanese POAG patients was analyzed from our international Trabectome database. The patients received Trabectome or a combined surgery with phacoemulsification and intraocular lens implantation. The primary outcome was intraocular pressure (IOP) reduction. Secondary outcomes included reduction of glaucoma medications, surgical complications, and success at 2y. Success was defined as: 1) IOP≤21 mm Hg and at least 20% IOP reduction from baseline after 3mo at any two consecutive visits; 2) no additional glaucoma surgery required.
RESULTS: A total of 42 Chinese POAG patients from three glaucoma centers were enrolled. Twelve patients underwent Trabectome surgery combined with phacoemulsification and intraocular lens implantation while the remainder underwent Trabectome surgery alone. Thirteen patients had a history of failed glaucoma surgery and were considered as complicated cases. In China data, the mean preoperative IOP was 21.4±1.23 mm Hg. The Trabectome lowered IOP to 17.9±1.8 mm Hg at 2y (P=0.05). The number of glaucoma medications also decreased significantly from a baseline of 2.0±0.9 to 1.1±0.8 at 2y post-surgery (P=0.04). The overall 2-year success rate was 78%, with patients undergoing combined surgery having a higher success rate compared with those undergoing Trabectome surgery alone (100% vs 76%). In Japan data, the mean preoperative IOP was 20.8±7.7 mm Hg. The Trabectome lowered IOP to 12.20±2.0 mm Hg at 2y. The number of glaucoma medications also decreased significantly from a baseline of 2.1±0.9 to 3.4±0.6 at 2y post-surgery. In all patients, no major complications were seen.
CONCLUSION: Surgery with the Trabectome appears to be an efficient and safe procedure in Chinese POAG patients in the long-term.

Entities:  

Keywords:  intraocular pressure; minimally invasive glaucoma surgeries; primary open angle glaucoma; surgical complications

Year:  2018        PMID: 29977805      PMCID: PMC6010386          DOI: 10.18240/ijo.2018.06.08

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  40 in total

Review 1.  Review and meta-analysis of ab-interno trabeculectomy outcomes.

Authors:  Kevin Kaplowitz; Igor I Bussel; Robert Honkanen; Joel S Schuman; Nils A Loewen
Journal:  Br J Ophthalmol       Date:  2016-01-05       Impact factor: 4.638

2.  Ab interno trabeculectomy: development of a novel device (Trabectome) and surgery for open-angle glaucoma.

Authors:  Brian A Francis; Robert F See; Narsing A Rao; Don S Minckler; George Baerveldt
Journal:  J Glaucoma       Date:  2006-02       Impact factor: 2.503

3.  Optical coherence tomography of the suprachoroid after CyPass Micro-Stent implantation for the treatment of open-angle glaucoma.

Authors:  Hady Saheb; Tsontcho Ianchulev; Iqbal Ike K Ahmed
Journal:  Br J Ophthalmol       Date:  2013-06-06       Impact factor: 4.638

4.  [Preliminary investigation on the safety and efficacy of Trabectome].

Authors:  Ping Huang; Huaizhou Wang; Huijuan Wu; Yanran Sun; Minshu Wang; Ying Cui; Weiqiang Qiu; Yiquan Yang; Zeqin Ren; Chun Zhang; Ningli Wang
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2015-02

5.  Coexistent primary open-angle glaucoma and cataract: preliminary analysis of treatment by cataract surgery and the iStent trabecular micro-bypass stent.

Authors:  Detlev Spiegel; Julian García-Feijoó; Julián García-Sánchez; Helene Lamielle
Journal:  Adv Ther       Date:  2008-05       Impact factor: 3.845

6.  Clinical results of ab interno trabeculotomy using the Trabectome in patients with pigmentary glaucoma compared to primary open angle glaucoma.

Authors:  Handan Akil; Vikas Chopra; Alex Huang; Nils Loewen; Jonathan Noguchi; Brian A Francis
Journal:  Clin Exp Ophthalmol       Date:  2016-04-07       Impact factor: 4.207

Review 7.  Ab interno approach to the subconjunctival space using a collagen glaucoma stent.

Authors:  Richard A Lewis
Journal:  J Cataract Refract Surg       Date:  2014-06-15       Impact factor: 3.351

8.  Trabectome surgery for primary and secondary open angle glaucomas.

Authors:  Jens F Jordan; Thomas Wecker; Christian van Oterendorp; Alexandra Anton; Thomas Reinhard; Daniel Boehringer; Matthias Neuburger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-26       Impact factor: 3.117

9.  Efficacy and Safety of Trabectome Surgery in Chinese Open-Angle Glaucoma.

Authors:  Jacky W Y Lee; Doris W F Yick; Susanna Tsang; Can Y F Yuen; Jimmy S M Lai
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

10.  Angle stability and outflow in dual blade ab interno trabeculectomy with active versus passive chamber management.

Authors:  Chao Wang; Yalong Dang; Susannah Waxman; Xiaobo Xia; Robert N Weinreb; Nils A Loewen
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

View more
  3 in total

1.  Viscotrabeculotomy versus trabeculectomy in the surgical treatment of open angle glaucoma: a single center, randomised controlled trial.

Authors:  Ahmed S Elwehidy; Tharwat H Mokbel; Nader H L Bayoumi; Amani E Badawi; Sherein M Hagras
Journal:  Jpn J Ophthalmol       Date:  2021-01-07       Impact factor: 2.447

Review 2.  Effectiveness and limitations of minimally invasive glaucoma surgery targeting Schlemm's canal.

Authors:  Masayuki Kasahara; Nobuyuki Shoji
Journal:  Jpn J Ophthalmol       Date:  2020-11-05       Impact factor: 2.447

Review 3.  Minimally Invasive Glaucoma Surgery: What Do We Know? Where Should We Go?

Authors:  Chen Xin; Huangzhou Wang; Ningli Wang
Journal:  Transl Vis Sci Technol       Date:  2020-04-23       Impact factor: 3.283

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.